Views & Analysis Gene editing: beyond the hype Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.
Partner Content Partner Content Targeting Solid & Liquid Malignancies with the Same CAR Cell and Gene Therapy
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
